PRIDE Syndrome: A Practical Way to Identify Adverse Skin Effects of EGFR Inhibitors

    October 2021 in “ Revista Medicina Cutánea Ibero-Latino-Americana ”
    Paula Johana Barba, Lucía Piccinelli, Betina De Andrés, Mariana Hurtado
    Studysummary This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on medicinacutaneaila.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Histopathologic Features of Erythematous Papulopustular Eruption to Epidermal Growth Factor Receptor Inhibitors in Cancer Patients Journal of Cutaneous Pathology · 2015
    2. The PRIDE Syndrome: Dermatological Side Effects of EGFR Inhibitors British Journal of Dermatology · 2006